The Indian pharmaceutical industry, reeling under the regulatory scanner of the US Food and Drugs Administration (FDA) for the past few years, is learning from their mistakes. Out of the 192 inspections held by the US FDA in India in 2017, only eight were referred for Official Action indicated (OAI) or ...
Read more: Indian pharma companies correcting mistakes in manufacturing standards